- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
E-Z-EM appoints executive for Asia
With a view to taking advantage of the imaging business in Japan, China, and the Pacific Rim, E-Z-EM has appointed Michael Dellario managing director for Asia. Dellario will assume responsibility for the company’s subsidiary, Toho Kagaku Kenkyusho.
With a view to taking advantage of the imaging business in Japan, China, and the Pacific Rim, E-Z-EM has appointed Michael Dellario managing director for Asia. Dellario will assume responsibility for the company’s subsidiary, Toho Kagaku Kenkyusho. He is charged with reorganizing Toho from a manufacturing-based organization to a sales and marketing group. Dellario began his career with AngioDynamics, a subsidiary of E-Z-EM, where he was director of marketing for various cardiology and interventional radiology product groups. In 1999, he joined E-Z-EM’s international operations department as sales and marketing director in Asia for both E-Z-EM and AngioDynamics.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
Surveillance Breast MRI Associated with Lower Risks of Advanced Second Breast Cancers
January 8th 2025After propensity score matching in a study of over 3,000 women with a personal history of breast cancer, researchers found that surveillance breast MRI facilitated a 59 percent lower risk in advanced presentations of second breast cancers.
